Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has earned an average recommendation of "Buy" from the five brokerages that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $38.80.

Several research firms recently commented on KNSA. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target on the stock. Wedbush reiterated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday.

Kiniksa Pharmaceuticals Price Performance

NASDAQ KNSA opened at $30.23 on Friday. The business has a 50 day simple moving average of $24.27 and a 200 day simple moving average of $21.90. Kiniksa Pharmaceuticals has a one year low of $17.38 and a one year high of $30.27. The stock has a market capitalization of $2.21 billion, a P/E ratio of -215.91 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same quarter last year, the firm posted ($0.25) earnings per share. The firm's revenue was up 72.5% on a year-over-year basis. Equities analysts expect that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

Insider Activity

In other news, CEO Sanj K. Patel sold 62,116 shares of the firm's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $27.33, for a total value of $1,697,630.28. Following the transaction, the chief executive officer now owns 96,674 shares in the company, valued at $2,642,100.42. This trade represents a 39.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ross Moat sold 27,594 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the sale, the insider now directly owns 9,415 shares of the company's stock, valued at $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 391,014 shares of company stock worth $10,101,143 over the last 90 days. 54.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Nuveen Asset Management LLC increased its position in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after acquiring an additional 54,361 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock valued at $2,414,000 after acquiring an additional 32,393 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $3,955,000. Globeflex Capital L P increased its position in shares of Kiniksa Pharmaceuticals by 217.1% during the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock valued at $1,752,000 after acquiring an additional 60,656 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Kiniksa Pharmaceuticals by 32.5% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 99,632 shares of the company's stock valued at $1,971,000 after acquiring an additional 24,463 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.